Stocktoria
Smith & Nephew plc SN.L
GB · London Stock Exchange · XLON · stock · Healthcare · website
Smith & Nephew plc financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $6.2B | $5.8B | $5.5B | $5.2B |
| Gross profit | $4.2B | $4.0B | $3.8B | $3.7B |
| R&D expense | $296.0M | $289.0M | $339.0M | $345.0M |
| SG&A expense | $2.8B | $2.7B | $2.6B | $2.4B |
| Operating income | $857.0M | $860.0M | $620.0M | $634.0M |
| Interest expense | $179.0M | $168.0M | $139.0M | $91.0M |
| Income tax | $154.0M | $86.0M | $27.0M | $12.0M |
| Net income | $625.0M | $412.0M | $263.0M | $223.0M |
| EPS (diluted) | $0.72 | $0.47 | $0.30 | $0.25 |
| Operating cash flow | $1.3B | $987.0M | $608.0M | $468.0M |
| Free cash flow | $852.0M | $606.0M | $181.0M | $110.0M |
| Cash & equivalents | $557.0M | $619.0M | $302.0M | $350.0M |
| Inventory | $2.1B | $2.4B | $2.4B | $2.2B |
| Total assets | $10.5B | $10.4B | $10.0B | $10.0B |
| Total liabilities | $5.2B | $5.1B | $4.8B | $4.7B |
| Shareholders' equity | $5.3B | $5.3B | $5.2B | $5.3B |
Growth · year-over-year · Revenue CAGR 5.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +6.1% | +4.7% | +6.4% | — |
| Net income growth | +51.7% | +56.7% | +17.9% | — |
| EPS growth | +52.3% | +56.1% | +20.4% | — |
| Free cash flow growth | +40.6% | +234.8% | +64.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · GB · as of 2025-12-31. Figures in GBp; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.